Toggle Summary
|
Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference
LAWRENCEVILLE, N.J. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33
|
View HTML
|
Toggle Summary
|
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or approximately one-third of the total, have been enrolled at 22 sites, including 20 patients in the treatment
|
View HTML
|
Toggle Summary
|
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical stage development company focused on DNA based immunotherapy and next generation vaccines,
|
View HTML
|
Toggle Summary
|
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer
Celsion’s Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases Granted an Accelerated Development Pathway Designation Provides Potential for an Expedited Regulatory Review. LAWRENCEVILLE, N.J. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a
|
View HTML
|
Toggle Summary
|
Celsion Corporation Announces Formation of Vaccine Advisory Board
Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced the formation
|
View HTML
|
Toggle Summary
|
Celsion Corporation Issues Letter to Stockholders
Discusses Broad-based DNA Vaccine Initiative, OVATION 2 Study, and Phase III OPTIMA Study Conclusions LAWRENCEVILLE, N.J. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced that Michael H.
|
View HTML
|
Toggle Summary
|
Celsion Corporation Files Provisional U.S. Patent Application for a Broad Range of Next Generation DNA Vaccines
The PLACCINE Platform Technology is Conceived to Enable Rapid Development of Vaccines That Can Address a Broad Range of Infectious Agents, including SARS-Associated Coronavirus (SARS-CoV) Patent Filing Claims a Novel Composition of Multiple Antigens and Use of a Synthetic Nano Delivery Technology
|
View HTML
|
Toggle Summary
|
CELSION CORPORATION ANNOUNCES CLOSING OF $35 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES
Lawrenceville, NJ , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced
|
View HTML
|
Toggle Summary
|
CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
LAWRENCEVILLE, NJ , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of its common stock at a purchase price of
|
View HTML
|
Toggle Summary
|
Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update
Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:
|
View HTML
|